 Jeffrey Olson
Concepts (319)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vitreous Body | 14 | 2020 | 102 | 2.970 |
Why?
| | Ophthalmologic Surgical Procedures | 5 | 2017 | 56 | 2.180 |
Why?
| | Angiogenesis Inhibitors | 11 | 2022 | 216 | 2.000 |
Why?
| | Retina | 11 | 2016 | 280 | 1.720 |
Why?
| | Glaucoma | 4 | 2017 | 216 | 1.610 |
Why?
| | Eye Foreign Bodies | 5 | 2016 | 23 | 1.590 |
Why?
| | Alloys | 4 | 2013 | 34 | 1.580 |
Why?
| | Macular Edema | 4 | 2022 | 41 | 1.540 |
Why?
| | Retinal Detachment | 6 | 2019 | 56 | 1.520 |
Why?
| | Vitrectomy | 7 | 2019 | 62 | 1.470 |
Why?
| | Diabetic Retinopathy | 6 | 2019 | 171 | 1.440 |
Why?
| | Glaucoma Drainage Implants | 3 | 2016 | 46 | 1.400 |
Why?
| | Retinal Diseases | 5 | 2017 | 86 | 1.240 |
Why?
| | Intraocular Pressure | 7 | 2017 | 296 | 1.220 |
Why?
| | Nanopores | 2 | 2020 | 7 | 1.200 |
Why?
| | Intravitreal Injections | 7 | 2022 | 54 | 1.170 |
Why?
| | Membranes, Artificial | 2 | 2020 | 68 | 1.160 |
Why?
| | Nanotechnology | 2 | 2020 | 119 | 1.100 |
Why?
| | Suction | 3 | 2015 | 32 | 1.010 |
Why?
| | Sutures | 3 | 2015 | 53 | 0.960 |
Why?
| | Choroidal Neovascularization | 4 | 2011 | 51 | 0.950 |
Why?
| | Anterior Eye Segment | 2 | 2017 | 9 | 0.950 |
Why?
| | Swine | 10 | 2017 | 743 | 0.930 |
Why?
| | Suture Techniques | 3 | 2015 | 121 | 0.930 |
Why?
| | Equipment Design | 6 | 2017 | 518 | 0.900 |
Why?
| | Lens Implantation, Intraocular | 2 | 2015 | 59 | 0.870 |
Why?
| | Retinitis | 1 | 2022 | 19 | 0.800 |
Why?
| | Retinal Vasculitis | 1 | 2022 | 10 | 0.800 |
Why?
| | Aneurysm | 1 | 2022 | 30 | 0.790 |
Why?
| | Vitreoretinopathy, Proliferative | 2 | 2019 | 12 | 0.730 |
Why?
| | Antibodies, Monoclonal | 6 | 2020 | 1355 | 0.730 |
Why?
| | Vascular Endothelial Growth Factor A | 6 | 2020 | 501 | 0.730 |
Why?
| | Immunosuppressive Agents | 3 | 2013 | 686 | 0.700 |
Why?
| | Retinal Vessels | 2 | 2015 | 63 | 0.690 |
Why?
| | Durapatite | 1 | 2020 | 35 | 0.690 |
Why?
| | Cytomegalovirus Retinitis | 2 | 2013 | 18 | 0.680 |
Why?
| | Complement System Proteins | 2 | 2020 | 306 | 0.670 |
Why?
| | Isoxazoles | 2 | 2013 | 54 | 0.670 |
Why?
| | Eye Injuries, Penetrating | 3 | 2016 | 16 | 0.670 |
Why?
| | Scleral Buckling | 3 | 2012 | 18 | 0.670 |
Why?
| | Endophthalmitis | 2 | 2017 | 28 | 0.660 |
Why?
| | Disease Models, Animal | 8 | 2020 | 3943 | 0.660 |
Why?
| | Stents | 2 | 2013 | 504 | 0.610 |
Why?
| | Fluorocarbons | 2 | 2012 | 109 | 0.580 |
Why?
| | Anterior Chamber | 1 | 2017 | 20 | 0.560 |
Why?
| | Glucocorticoids | 2 | 2020 | 575 | 0.550 |
Why?
| | Transducers | 1 | 2017 | 27 | 0.550 |
Why?
| | Strabismus | 1 | 2017 | 28 | 0.550 |
Why?
| | Sclera | 2 | 2015 | 36 | 0.530 |
Why?
| | Filtering Surgery | 1 | 2016 | 22 | 0.530 |
Why?
| | Trabeculectomy | 1 | 2017 | 71 | 0.520 |
Why?
| | Surgical Instruments | 2 | 2013 | 52 | 0.520 |
Why?
| | Fovea Centralis | 2 | 2006 | 10 | 0.510 |
Why?
| | Retinal Perforations | 2 | 2005 | 14 | 0.500 |
Why?
| | Ocular Hypertension | 1 | 2016 | 64 | 0.500 |
Why?
| | Drug Resistance, Multiple, Viral | 2 | 2013 | 11 | 0.500 |
Why?
| | Ophthalmology | 2 | 2013 | 81 | 0.490 |
Why?
| | Lenses, Intraocular | 1 | 2015 | 43 | 0.480 |
Why?
| | Laser Therapy | 1 | 2017 | 130 | 0.480 |
Why?
| | Monitoring, Physiologic | 1 | 2017 | 267 | 0.480 |
Why?
| | Lasers | 1 | 2015 | 132 | 0.470 |
Why?
| | Device Removal | 1 | 2016 | 137 | 0.460 |
Why?
| | Prostheses and Implants | 1 | 2016 | 135 | 0.460 |
Why?
| | Tomography, Optical Coherence | 7 | 2015 | 182 | 0.460 |
Why?
| | Ischemia | 2 | 2017 | 395 | 0.450 |
Why?
| | Antiviral Agents | 2 | 2013 | 704 | 0.450 |
Why?
| | Fluorescein Angiography | 9 | 2012 | 141 | 0.440 |
Why?
| | Rabbits | 3 | 2020 | 761 | 0.430 |
Why?
| | Models, Cardiovascular | 1 | 2015 | 190 | 0.430 |
Why?
| | Retinal Degeneration | 2 | 2015 | 37 | 0.420 |
Why?
| | Animals | 18 | 2020 | 34501 | 0.420 |
Why?
| | Artificial Lens Implant Migration | 1 | 2013 | 3 | 0.420 |
Why?
| | Choroid | 3 | 2015 | 61 | 0.420 |
Why?
| | Macular Degeneration | 6 | 2015 | 157 | 0.420 |
Why?
| | Viscosupplements | 1 | 2012 | 10 | 0.410 |
Why?
| | Gravitation | 1 | 2012 | 16 | 0.410 |
Why?
| | Silicone Oils | 1 | 2012 | 26 | 0.410 |
Why?
| | Silicon | 1 | 2012 | 14 | 0.410 |
Why?
| | Pupil Disorders | 1 | 2012 | 5 | 0.400 |
Why?
| | Eye Enucleation | 1 | 2012 | 11 | 0.400 |
Why?
| | Iris | 1 | 2012 | 19 | 0.400 |
Why?
| | Viremia | 1 | 2013 | 130 | 0.400 |
Why?
| | Quantum Dots | 1 | 2012 | 36 | 0.400 |
Why?
| | Silicone Elastomers | 1 | 2012 | 8 | 0.390 |
Why?
| | Prosthesis Implantation | 1 | 2013 | 143 | 0.390 |
Why?
| | Uveitis, Posterior | 1 | 2012 | 12 | 0.390 |
Why?
| | Surgical Stapling | 1 | 2012 | 13 | 0.390 |
Why?
| | Electric Stimulation Therapy | 1 | 2012 | 60 | 0.380 |
Why?
| | Fluocinolone Acetonide | 1 | 2012 | 19 | 0.380 |
Why?
| | Vitreous Hemorrhage | 2 | 2015 | 5 | 0.380 |
Why?
| | Cataract Extraction | 1 | 2013 | 96 | 0.370 |
Why?
| | Models, Biological | 4 | 2015 | 1693 | 0.370 |
Why?
| | Vascular Endothelial Growth Factors | 1 | 2011 | 65 | 0.370 |
Why?
| | Materials Testing | 1 | 2012 | 346 | 0.340 |
Why?
| | Cytomegalovirus | 2 | 2013 | 153 | 0.340 |
Why?
| | Oxygen | 1 | 2015 | 901 | 0.340 |
Why?
| | Humans | 47 | 2022 | 128524 | 0.330 |
Why?
| | Anti-Inflammatory Agents | 1 | 2012 | 469 | 0.300 |
Why?
| | Interleukin 1 Receptor Antagonist Protein | 1 | 2009 | 250 | 0.290 |
Why?
| | Biocompatible Materials | 1 | 2012 | 395 | 0.290 |
Why?
| | Electroretinography | 5 | 2016 | 45 | 0.280 |
Why?
| | von Hippel-Lindau Disease | 1 | 2007 | 11 | 0.280 |
Why?
| | Injections | 5 | 2012 | 170 | 0.270 |
Why?
| | Pigment Epithelium of Eye | 2 | 2006 | 34 | 0.270 |
Why?
| | Puerperal Disorders | 1 | 2007 | 30 | 0.270 |
Why?
| | Recombinant Fusion Proteins | 4 | 2022 | 632 | 0.270 |
Why?
| | Drug Implants | 2 | 2020 | 82 | 0.260 |
Why?
| | Uveal Diseases | 1 | 2006 | 5 | 0.260 |
Why?
| | Ocular Hypotension | 1 | 2006 | 10 | 0.260 |
Why?
| | Fusobacterium Infections | 1 | 2006 | 6 | 0.260 |
Why?
| | Antibodies, Monoclonal, Humanized | 6 | 2015 | 759 | 0.260 |
Why?
| | Pharyngeal Diseases | 1 | 2006 | 14 | 0.260 |
Why?
| | Needles | 2 | 2017 | 57 | 0.260 |
Why?
| | Epiretinal Membrane | 1 | 2005 | 7 | 0.260 |
Why?
| | Ciliary Body | 1 | 2006 | 33 | 0.260 |
Why?
| | Telangiectasis | 1 | 2005 | 6 | 0.250 |
Why?
| | Visual Acuity | 7 | 2019 | 320 | 0.250 |
Why?
| | Rats, Inbred BN | 3 | 2011 | 53 | 0.250 |
Why?
| | Dementia | 2 | 2022 | 227 | 0.240 |
Why?
| | Uveitis | 1 | 2006 | 127 | 0.240 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 3 | 2022 | 89 | 0.240 |
Why?
| | Female | 26 | 2022 | 68127 | 0.240 |
Why?
| | Kidney Transplantation | 2 | 2013 | 604 | 0.230 |
Why?
| | Injections, Intraocular | 2 | 2015 | 10 | 0.230 |
Why?
| | Polypropylenes | 2 | 2015 | 13 | 0.230 |
Why?
| | Middle Aged | 17 | 2019 | 30893 | 0.210 |
Why?
| | Laser Coagulation | 3 | 2012 | 57 | 0.200 |
Why?
| | Autoimmune Diseases | 1 | 2006 | 423 | 0.200 |
Why?
| | Optic Atrophy | 1 | 2022 | 10 | 0.200 |
Why?
| | Hearing Loss, Central | 1 | 2022 | 5 | 0.200 |
Why?
| | Bevacizumab | 6 | 2015 | 131 | 0.200 |
Why?
| | Rats | 4 | 2012 | 5168 | 0.190 |
Why?
| | Retinal Vein Occlusion | 2 | 2015 | 13 | 0.190 |
Why?
| | Cell Count | 2 | 2012 | 314 | 0.190 |
Why?
| | Dialysis | 1 | 2020 | 18 | 0.180 |
Why?
| | Leukemia, Megakaryoblastic, Acute | 1 | 2000 | 10 | 0.170 |
Why?
| | Orbital Neoplasms | 1 | 2000 | 20 | 0.170 |
Why?
| | Time Factors | 4 | 2017 | 6503 | 0.170 |
Why?
| | Adsorption | 1 | 2020 | 138 | 0.170 |
Why?
| | Follow-Up Studies | 5 | 2015 | 4898 | 0.160 |
Why?
| | Male | 21 | 2019 | 62883 | 0.160 |
Why?
| | Adult | 11 | 2022 | 35315 | 0.160 |
Why?
| | Biomarkers | 2 | 2020 | 3881 | 0.150 |
Why?
| | Wet Macular Degeneration | 1 | 2019 | 46 | 0.150 |
Why?
| | Fluorescein-5-isothiocyanate | 2 | 2009 | 36 | 0.150 |
Why?
| | Eye Diseases, Hereditary | 1 | 2018 | 11 | 0.150 |
Why?
| | Geographic Atrophy | 1 | 2019 | 69 | 0.150 |
Why?
| | Miniaturization | 2 | 2015 | 24 | 0.150 |
Why?
| | Dextrans | 2 | 2009 | 82 | 0.150 |
Why?
| | Iris Diseases | 1 | 2017 | 6 | 0.140 |
Why?
| | Choroid Diseases | 1 | 2017 | 10 | 0.140 |
Why?
| | Glomerulonephritis, Membranoproliferative | 1 | 1997 | 13 | 0.140 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2019 | 814 | 0.140 |
Why?
| | Dark Adaptation | 2 | 2012 | 14 | 0.140 |
Why?
| | Hypertension | 1 | 2006 | 1238 | 0.140 |
Why?
| | Antimony | 1 | 2016 | 5 | 0.140 |
Why?
| | Infliximab | 2 | 2007 | 100 | 0.130 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2014 | 1943 | 0.130 |
Why?
| | Aged, 80 and over | 6 | 2019 | 7040 | 0.130 |
Why?
| | Polymers | 1 | 2020 | 471 | 0.130 |
Why?
| | Pressure | 1 | 2017 | 239 | 0.130 |
Why?
| | Sclerostomy | 1 | 2015 | 4 | 0.130 |
Why?
| | Foreign-Body Migration | 1 | 2016 | 34 | 0.120 |
Why?
| | Treatment Outcome | 9 | 2016 | 10163 | 0.120 |
Why?
| | Gyrate Atrophy | 1 | 2015 | 2 | 0.120 |
Why?
| | Aged | 10 | 2020 | 21971 | 0.120 |
Why?
| | Vitreoretinal Surgery | 1 | 2015 | 3 | 0.120 |
Why?
| | Eye Infections, Bacterial | 1 | 2015 | 26 | 0.120 |
Why?
| | Vitreous Detachment | 1 | 2015 | 7 | 0.120 |
Why?
| | Stress, Mechanical | 1 | 2017 | 465 | 0.120 |
Why?
| | Diagnostic Techniques, Ophthalmological | 1 | 2015 | 38 | 0.120 |
Why?
| | Equipment Failure Analysis | 1 | 2015 | 131 | 0.120 |
Why?
| | Partial Pressure | 1 | 2015 | 29 | 0.120 |
Why?
| | Health Knowledge, Attitudes, Practice | 2 | 2014 | 1271 | 0.120 |
Why?
| | Hemoglobin SC Disease | 1 | 2015 | 13 | 0.120 |
Why?
| | Prosthesis Failure | 1 | 2016 | 118 | 0.120 |
Why?
| | Biopsy, Needle | 1 | 2015 | 189 | 0.120 |
Why?
| | Feedback | 1 | 2015 | 159 | 0.120 |
Why?
| | Oculomotor Muscles | 1 | 2014 | 38 | 0.120 |
Why?
| | International Normalized Ratio | 1 | 2014 | 47 | 0.120 |
Why?
| | Protein Binding | 1 | 2020 | 2097 | 0.110 |
Why?
| | Postoperative Care | 1 | 2015 | 243 | 0.110 |
Why?
| | Exchange Transfusion, Whole Blood | 1 | 2013 | 14 | 0.110 |
Why?
| | Down Syndrome | 1 | 2000 | 470 | 0.110 |
Why?
| | Retinal Artery Occlusion | 1 | 2013 | 8 | 0.110 |
Why?
| | In Vitro Techniques | 1 | 2015 | 1043 | 0.110 |
Why?
| | Tendons | 1 | 2014 | 127 | 0.110 |
Why?
| | Warfarin | 1 | 2014 | 147 | 0.110 |
Why?
| | Metabolomics | 1 | 2018 | 597 | 0.100 |
Why?
| | Specific Gravity | 1 | 2012 | 10 | 0.100 |
Why?
| | Transducers, Pressure | 1 | 2012 | 13 | 0.100 |
Why?
| | Diabetes Mellitus, Type 2 | 2 | 2012 | 2430 | 0.100 |
Why?
| | Erythrocyte Transfusion | 1 | 2015 | 182 | 0.100 |
Why?
| | Adaptation, Ocular | 1 | 2012 | 4 | 0.100 |
Why?
| | Research Design | 1 | 2019 | 1038 | 0.100 |
Why?
| | Minerals | 1 | 2012 | 39 | 0.100 |
Why?
| | Rats, Mutant Strains | 1 | 2012 | 24 | 0.100 |
Why?
| | Pupil | 1 | 2012 | 13 | 0.100 |
Why?
| | Viscosity | 1 | 2012 | 89 | 0.100 |
Why?
| | Antineoplastic Agents | 2 | 2020 | 2058 | 0.100 |
Why?
| | Acetates | 1 | 2012 | 97 | 0.100 |
Why?
| | Corneal Endothelial Cell Loss | 1 | 2012 | 2 | 0.100 |
Why?
| | Retinal Neovascularization | 1 | 2012 | 22 | 0.100 |
Why?
| | Sodium Chloride | 1 | 2012 | 138 | 0.100 |
Why?
| | Endothelium, Corneal | 1 | 2012 | 16 | 0.100 |
Why?
| | Swine, Miniature | 1 | 2012 | 78 | 0.100 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2007 | 1190 | 0.100 |
Why?
| | Electrodes, Implanted | 1 | 2012 | 106 | 0.100 |
Why?
| | Microsurgery | 1 | 2012 | 69 | 0.090 |
Why?
| | Retinal Ganglion Cells | 1 | 2012 | 97 | 0.090 |
Why?
| | Drug Combinations | 1 | 2012 | 323 | 0.090 |
Why?
| | Adolescent | 4 | 2019 | 20213 | 0.090 |
Why?
| | Bruch Membrane | 1 | 2011 | 6 | 0.090 |
Why?
| | Gold | 1 | 2012 | 117 | 0.090 |
Why?
| | Polyglycolic Acid | 1 | 2011 | 42 | 0.090 |
Why?
| | Registries | 1 | 2019 | 1878 | 0.090 |
Why?
| | Administration, Oral | 1 | 2013 | 757 | 0.090 |
Why?
| | Drug Compounding | 1 | 2011 | 95 | 0.090 |
Why?
| | Dissection | 1 | 2011 | 56 | 0.090 |
Why?
| | Computer Simulation | 1 | 2015 | 939 | 0.090 |
Why?
| | Delayed-Action Preparations | 1 | 2011 | 176 | 0.090 |
Why?
| | Models, Animal | 1 | 2012 | 367 | 0.080 |
Why?
| | Atrial Fibrillation | 1 | 2014 | 378 | 0.080 |
Why?
| | Anemia, Sickle Cell | 1 | 2013 | 252 | 0.080 |
Why?
| | Retrospective Studies | 8 | 2015 | 14460 | 0.080 |
Why?
| | Lactic Acid | 1 | 2011 | 295 | 0.080 |
Why?
| | Cell Survival | 1 | 2012 | 1077 | 0.080 |
Why?
| | Bacteria | 1 | 2015 | 811 | 0.080 |
Why?
| | Scotoma | 1 | 2008 | 5 | 0.080 |
Why?
| | Proliferating Cell Nuclear Antigen | 1 | 2007 | 50 | 0.070 |
Why?
| | Optic Neuropathy, Ischemic | 1 | 2007 | 30 | 0.070 |
Why?
| | Papilledema | 1 | 2007 | 39 | 0.070 |
Why?
| | Severity of Illness Index | 2 | 2014 | 2736 | 0.070 |
Why?
| | Pilot Projects | 1 | 2012 | 1558 | 0.070 |
Why?
| | Visual Fields | 3 | 2007 | 88 | 0.070 |
Why?
| | RNA, Catalytic | 1 | 2007 | 185 | 0.070 |
Why?
| | Retinitis Pigmentosa | 1 | 2006 | 20 | 0.070 |
Why?
| | Glycogen Storage Disease Type IIb | 1 | 2006 | 25 | 0.070 |
Why?
| | Triamcinolone Acetonide | 1 | 2006 | 27 | 0.070 |
Why?
| | Fusobacterium necrophorum | 1 | 2006 | 1 | 0.070 |
Why?
| | Polyethylene Glycols | 1 | 2011 | 597 | 0.060 |
Why?
| | Indocyanine Green | 1 | 2005 | 19 | 0.060 |
Why?
| | Vision, Low | 3 | 2013 | 16 | 0.060 |
Why?
| | Myopia | 1 | 2006 | 47 | 0.060 |
Why?
| | Coloring Agents | 1 | 2005 | 76 | 0.060 |
Why?
| | Eye Injuries | 1 | 2006 | 45 | 0.060 |
Why?
| | Infusions, Intravenous | 1 | 2006 | 384 | 0.060 |
Why?
| | Young Adult | 2 | 2019 | 12320 | 0.060 |
Why?
| | Staining and Labeling | 1 | 2005 | 139 | 0.060 |
Why?
| | Syndrome | 1 | 2006 | 335 | 0.060 |
Why?
| | Cataract | 1 | 2006 | 194 | 0.050 |
Why?
| | Multivariate Analysis | 2 | 2019 | 1494 | 0.050 |
Why?
| | Diagnosis, Differential | 1 | 2007 | 1416 | 0.050 |
Why?
| | Ranibizumab | 2 | 2013 | 20 | 0.050 |
Why?
| | Blindness | 2 | 2013 | 37 | 0.050 |
Why?
| | Keratitis | 1 | 2000 | 11 | 0.040 |
Why?
| | Postoperative Complications | 1 | 2012 | 2479 | 0.040 |
Why?
| | Exophthalmos | 1 | 2000 | 17 | 0.040 |
Why?
| | Chronic Disease | 1 | 2006 | 1701 | 0.040 |
Why?
| | Immunophenotyping | 1 | 2000 | 312 | 0.040 |
Why?
| | Xanthine | 1 | 2018 | 7 | 0.040 |
Why?
| | Tomography, X-Ray Computed | 2 | 2016 | 2521 | 0.040 |
Why?
| | Combined Modality Therapy | 2 | 2013 | 1209 | 0.040 |
Why?
| | Electrooculography | 1 | 1997 | 12 | 0.040 |
Why?
| | Visual Field Tests | 1 | 1997 | 16 | 0.040 |
Why?
| | Color Vision Defects | 1 | 1997 | 7 | 0.040 |
Why?
| | Fundus Oculi | 1 | 1997 | 61 | 0.030 |
Why?
| | Purines | 1 | 2018 | 169 | 0.030 |
Why?
| | Cohort Studies | 2 | 2019 | 5369 | 0.030 |
Why?
| | Odds Ratio | 1 | 2019 | 1022 | 0.030 |
Why?
| | Photic Stimulation | 1 | 1997 | 240 | 0.030 |
Why?
| | Child | 2 | 2015 | 20721 | 0.030 |
Why?
| | Vision Disorders | 1 | 1997 | 135 | 0.030 |
Why?
| | Microbiological Techniques | 1 | 2015 | 30 | 0.030 |
Why?
| | Colony Count, Microbial | 1 | 2015 | 116 | 0.030 |
Why?
| | Endotamponade | 1 | 2015 | 2 | 0.030 |
Why?
| | Myopia, Degenerative | 1 | 2015 | 4 | 0.030 |
Why?
| | Metabolome | 1 | 2018 | 318 | 0.030 |
Why?
| | Tenon Capsule | 1 | 2014 | 3 | 0.030 |
Why?
| | Tissue Adhesions | 1 | 2015 | 29 | 0.030 |
Why?
| | Mass Spectrometry | 1 | 2018 | 660 | 0.030 |
Why?
| | Photography | 1 | 2015 | 98 | 0.030 |
Why?
| | Atrophy | 1 | 2015 | 172 | 0.030 |
Why?
| | Conjunctiva | 1 | 2014 | 51 | 0.030 |
Why?
| | Biometry | 1 | 2014 | 69 | 0.030 |
Why?
| | Disease Progression | 2 | 2015 | 2603 | 0.030 |
Why?
| | Pregnancy | 1 | 2007 | 6297 | 0.030 |
Why?
| | Glucose | 1 | 2018 | 983 | 0.030 |
Why?
| | Risk Factors | 2 | 2019 | 9727 | 0.030 |
Why?
| | Fatty Acids, Omega-3 | 1 | 2014 | 137 | 0.030 |
Why?
| | Retreatment | 1 | 2012 | 70 | 0.020 |
Why?
| | Risk Assessment | 2 | 2014 | 3256 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2014 | 857 | 0.020 |
Why?
| | Oxidative Stress | 1 | 2018 | 1188 | 0.020 |
Why?
| | Global Health | 1 | 2014 | 326 | 0.020 |
Why?
| | Survival Analysis | 1 | 2014 | 1265 | 0.020 |
Why?
| | Proportional Hazards Models | 1 | 2014 | 1208 | 0.020 |
Why?
| | Health Care Costs | 1 | 2014 | 395 | 0.020 |
Why?
| | Phenotype | 1 | 2019 | 3050 | 0.020 |
Why?
| | Antioxidants | 1 | 2014 | 543 | 0.020 |
Why?
| | Anticoagulants | 1 | 2014 | 613 | 0.020 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2014 | 411 | 0.020 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2009 | 71 | 0.020 |
Why?
| | Clinical Trials, Phase I as Topic | 1 | 2009 | 49 | 0.020 |
Why?
| | Comorbidity | 1 | 2014 | 1540 | 0.020 |
Why?
| | Colorado | 1 | 2019 | 4392 | 0.020 |
Why?
| | Prospective Studies | 2 | 2012 | 7043 | 0.020 |
Why?
| | Retinal Artery | 1 | 2007 | 16 | 0.020 |
Why?
| | Cerebral Angiography | 1 | 2007 | 107 | 0.020 |
Why?
| | Lysosomal-Associated Membrane Protein 2 | 1 | 2006 | 28 | 0.020 |
Why?
| | Infant | 1 | 2000 | 8913 | 0.020 |
Why?
| | Frameshift Mutation | 1 | 2006 | 31 | 0.020 |
Why?
| | Secondary Prevention | 1 | 2007 | 220 | 0.020 |
Why?
| | Prognosis | 1 | 2014 | 3780 | 0.020 |
Why?
| | Anti-Bacterial Agents | 1 | 2015 | 1667 | 0.020 |
Why?
| | Adrenal Cortex Hormones | 1 | 2008 | 518 | 0.010 |
Why?
| | Double-Blind Method | 1 | 2007 | 1860 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2007 | 2674 | 0.010 |
Why?
| | Aging | 1 | 2008 | 1770 | 0.010 |
Why?
|
|
Olson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|